Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 491 to 500 of 903

TitleReference numberPublishedLast updated
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancerTA654
Pembrolizumab with axitinib for untreated advanced renal cell carcinomaTA650
Naldemedine for treating opioid-induced constipationTA651
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphomaTA649
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)TA647
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)TA646
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphomaTA641
Gilteritinib for treating relapsed or refractory acute myeloid leukaemiaTA642
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancerTA643
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplantTA640

Results per page

  1. 10
  2. 25
  3. 50
  4. All